RxDoctor Payments Data

Eileen Daetsch, NP

Adult Health · Williamsville, NYNPI 1477644508

Payments from drug & device makers

$2,929in general payments, 2019–2025

Across 110 payments — averaging $26.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$355
  • AstraZeneca$340
  • Recor Medical Inc$299
  • E.r. Squibb & Sons, L.L.C.$233
  • Merck$192
  • Johnson & Johnson$159
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$2,929100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,929 in reported general payments places this provider in the 85th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$15,633
Medicare patients
86
Services billed
179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban126$158,004
Repatha SureclickEvolocumab89$81,248
JardianceEmpagliflozin52$68,904
FarxigaDapagliflozin Propanediol34$53,326
EntrestoSacubitril/Valsartan33$47,323
XareltoRivaroxaban25$31,799
Repatha SyringeEvolocumab41$22,054
BrilintaTicagrelor18$19,488
Repatha PushtronexEvolocumab18$11,962
Metoprolol Succinate239$5,123
Ezetimibe159$3,975
Rosuvastatin Calcium210$3,379
Icosapent Ethyl11$3,358
Atorvastatin Calcium166$2,839
Amlodipine Besylate185$2,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$54$158,004126 claims
AstraZenecaFarxiga, Brilinta$340$72,81552 claims
NovartisEntresto$122$47,32333 claims
Johnson & JohnsonXarelto$159$31,79925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,828 adult health providers in New York.

Other adult health in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →